FORESEE PHARMACEUTICALS CO., LTD. Financials Foresee Pharmaceuticals Co., Ltd.
Equities
6576
TW0006576002
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.5 TWD | 0.00% |
|
-15.14% | -13.20% |
| 24/06 | Foresee Pharmaceuticals Co., Ltd. announced a financing transaction | CI |
| 14/05 | Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 5,848 | 10,474 | 14,047 | 10,797 | 13,062 | 11,350 |
| Enterprise Value (EV) 1 | 5,365 | 8,962 | 12,779 | 10,148 | 13,062 | 11,466 |
| P/E ratio | -11.5 x | -17.8 x | -24.6 x | -22.9 x | -11.8 x | -130 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 77.8 x | 45.5 x | 62.1 x | 35.8 x | 67 x | 12.4 x |
| EV / Revenue | 71.3 x | 38.9 x | 56.5 x | 33.7 x | 67 x | 12.5 x |
| EV / EBITDA | -12.4 x | -20.6 x | -26.2 x | -24.3 x | -13.6 x | 1,911 x |
| EV / FCF | -10 x | -13 x | -58 x | -35.8 x | 14.4 x | -145 x |
| FCF Yield | -9.96% | -7.67% | -1.72% | -2.79% | 6.96% | -0.69% |
| Price to Book | 6.53 x | 5.73 x | 10.7 x | 11.9 x | - | -96 x |
| Nbr of stocks (in thousands) | 1,00,313 | 1,16,898 | 1,17,552 | 1,18,124 | 1,35,777 | 1,35,926 |
| Reference price 2 | 58.30 | 89.60 | 119.5 | 91.40 | 96.20 | 83.50 |
| Announcement Date | 24/03/20 | 24/03/21 | 25/03/22 | 24/02/23 | 28/03/24 | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | 75.2 | 230.4 | 226 | 301.5 | 195 | 916 |
| EBITDA 1 | -430.9 | -435.3 | -487.2 | -418.3 | -958.3 | 6 |
| EBIT 1 | -470.1 | -484.8 | -538.6 | -469.4 | -1,024 | -85 |
| Operating Margin | -625.18% | -210.38% | -238.3% | -155.7% | -524.88% | -9.28% |
| Earnings before Tax (EBT) 1 | -470 | -482.8 | -528 | -438.1 | -996.1 | -76 |
| Net income 1 | -487.2 | -510.7 | -569.3 | -472.6 | -1,036 | -76 |
| Net margin | -647.91% | -221.63% | -251.86% | -156.76% | -531.33% | -8.3% |
| EPS 2 | -5.080 | -5.040 | -4.850 | -4.000 | -8.140 | -0.6400 |
| Free Cash Flow 1 | -534.3 | -687.6 | -220.2 | -283.3 | 909.1 | -79 |
| FCF margin | -710.58% | -298.38% | -97.42% | -93.97% | 466.1% | -8.62% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 24/03/20 | 24/03/21 | 25/03/22 | 24/02/23 | 28/03/24 | - |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.446 | 66.98 | 206.7 | 18.1 | 9.756 | 28.41 | 37.49 | 60.72 | 68.42 | 103.9 | 121 | 548 | 131 |
| EBITDA 1 | -180.5 | -108.1 | 42.39 | - | - | -156.5 | -255.9 | -223.2 | -322.7 | -114.4 | -103 | 315 | -103 |
| EBIT 1 | -193 | -120.3 | 30.69 | -175.5 | -204.4 | -173.9 | -273.6 | -241.8 | -334.5 | -134.7 | -126 | 292 | -125 |
| Operating Margin | -43,284.08% | -179.63% | 14.85% | -969.15% | -2,094.61% | -612.13% | -729.74% | -398.16% | -488.88% | -129.68% | -104.13% | 53.28% | -95.42% |
| Earnings before Tax (EBT) 1 | -192.6 | -116.1 | 42.42 | -160.3 | -204.2 | -172.9 | -269.2 | -215.8 | -338.1 | -107.9 | -123 | 294 | -125 |
| Net income 1 | -193.2 | -122.3 | 21.8 | -164.1 | -208.1 | -179.2 | -281.9 | -236.6 | -338.6 | -119.5 | -123 | 294 | -125 |
| Net margin | -43,323.77% | -182.6% | 10.55% | -906.31% | -2,132.56% | -631.03% | -752.09% | -389.57% | -494.81% | -115.11% | -101.65% | 53.65% | -95.42% |
| EPS 2 | -1.640 | -1.040 | 0.1800 | -1.390 | -1.760 | -1.520 | -2.370 | -1.740 | -2.530 | -0.8800 | -1.040 | 2.490 | -1.050 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 25/03/22 | 13/05/22 | 10/08/22 | 11/11/22 | 24/02/23 | 15/05/23 | 14/08/23 | 10/11/23 | 28/03/24 | 14/05/24 | - | - | - |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 116 |
| Net Cash position 1 | 484 | 1,512 | 1,269 | 648 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 19.33 x |
| Free Cash Flow 1 | -534 | -688 | -220 | -283 | 909 | -79 |
| ROE (net income / shareholders' equity) | -69.9% | -37.5% | -36.2% | -42.4% | -96.2% | - |
| ROA (Net income/ Total Assets) | -59.6% | -32.9% | -30.4% | -32.1% | -65.6% | -12.4% |
| Assets 1 | 816.9 | 1,554 | 1,871 | 1,473 | 1,580 | 612.9 |
| Book Value Per Share 2 | 8.930 | 15.60 | 11.20 | 7.710 | - | -0.8700 |
| Cash Flow per Share 2 | -4.670 | -6.650 | -1.820 | - | - | -0.1000 |
| Capex 1 | 86.5 | 12.8 | 6.86 | 50.1 | 43.6 | 45 |
| Capex / Sales | 115.06% | 5.55% | 3.03% | 16.61% | 22.33% | 4.91% |
| Announcement Date | 24/03/20 | 24/03/21 | 25/03/22 | 24/02/23 | 28/03/24 | - |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
83.5
TWD
Average target price
153
TWD
Spread / Average Target
+83.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.20% | 348M | |
| +38.65% | 39.1B | |
| -8.62% | 38.76B | |
| +26.95% | 31.24B | |
| +10.74% | 25.9B | |
| -13.50% | 25.8B | |
| +44.87% | 14.06B | |
| +34.36% | 13.12B | |
| -7.14% | 11.32B | |
| -12.61% | 10.68B |
- Stock Market
- Equities
- 6576 Stock
- Financials Foresee Pharmaceuticals Co., Ltd.
